Nano Innovation for Cancer (NICE)


At a Glance
  • Status: Active Consortium
  • Year Launched: 2013
  • Initiating Organization: BioAlliance Pharma
  • Initiator Type: Industry
  • Disease focus:
    Oncology
  • Location: Europe

Abstract

Nano Innovation for Cancer (NICE) is the first consortium of nanomedicine stakeholders in France focused on aspects of characterization and industrialization of processes specific to nanodrugs. The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France.

Mission

The NICE consortium includes partners with deep expertise in the field of nanomedicine. Its mission is to build a platform to accelerate the development and industrialization of nanomedicine in France by capitalizing on the strong and complementary expertise of each partner.

Consortium History

July 2013: Consortium launch
October 2014: Second grant announced

Financing

An amount of €4.3 million was allocated directly to BioAlliance Pharma to accelerate the industrial development of Livatag. The second payment of 1.144 k€ from Bpifrance was announced in October 2014 as part as the funding to support the NICE consortium.

Sponsors & Partners

BioAlliance Pharma

CEA-Leti

DBI

Institut Galien Paris Sud

Nanobiotix


Last Updated: 04/08/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.